Aquestive Therapeutics (AQST) Other Accumulated Expenses (2017 - 2020)

Aquestive Therapeutics' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $201000.0 for Q4 2020.

• On a quarterly basis, Other Accumulated Expenses fell 17.28% year-over-year to $201000.0 in Q4 2020; TTM through Dec 2020 was $201000.0, a 17.28% decrease from a year earlier, with the FY2020 full-year figure at $201000.0, down 17.28% from the prior year.
• Other Accumulated Expenses retreated to $201000.0 in Q4 2020 per AQST's latest filing, from $284000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $284000.0 in Q3 2020 and bottomed at $97000.0 in Q1 2020.
• The 4-year median for Other Accumulated Expenses is $215000.0 (2018), against an average of $213916.7.
• Biggest YoY gain for Other Accumulated Expenses was 54.35% in 2020; the steepest drop was 49.48% in 2020.
• Year by year, Other Accumulated Expenses stood at $225000.0 in 2017, then dropped by 8.0% to $207000.0 in 2018, then advanced by 17.39% to $243000.0 in 2019, then fell by 17.28% to $201000.0 in 2020.
• Per Business Quant, the three latest AQST Other Accumulated Expenses figures stand at $201000.0 (Q4 2020), $284000.0 (Q3 2020), and $223000.0 (Q2 2020).